Cargando…

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC

BACKGROUND: Combined small cell lung cancer (c-SCLC) distinguishes itself from small cell lung cancer (SCLC) due to its inclusion of both SCLC and non-small cell lung cancer (NSCLC) components. Few studies have compared clinicopathological characteristics, prognosis and factors affecting survival. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chenyue, Shang, Xiaoling, Sun, Jian, Li, Zhenxiang, Lin, Jiamao, Zhao, Chenglong, Wang, Haiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536838/ https://www.ncbi.nlm.nih.gov/pubmed/34703294 http://dx.doi.org/10.2147/IJGM.S332725

Ejemplares similares

Radiotherapy may improve survival of ES-SCLC with distant metastasis only for patients with one metastatic site: A population-based study
por: Shang, Xiaoling, et al.
Publicado: (2020)

Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting
por: Zhang, Chenyue, et al.
Publicado: (2021)

Impact of Socioeconomic Factors on Overall Survival in SCLC
por: Roof, Logan, et al.
Publicado: (2022)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Incorporating the Number of PLN into the AJCC Stage Could Better Predict the Survival for Patients with NSCLC: A Large Population-Based Study
por: Shang, Xiaoling, et al.
Publicado: (2020)

A Novel Nomogram including AJCC Stages Could Better Predict Survival for NSCLC Patients Who Underwent Surgery: A Large Population-Based Study
por: Shang, Xiaoling, et al.
Publicado: (2020)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies
por: Wang, Haiyong, et al.
Publicado: (2022)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types
por: Zhang, Chenyue, et al.
Publicado: (2020)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023)

Survival, Chemotherapy and Chemosensitivity Predicted by CTC Cultured In Vitro of SCLC Patients
por: Ju, Lixia, et al.
Publicado: (2021)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
por: Lin, Jiamao, et al.
Publicado: (2021)

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
por: Domvri, Kalliopi, et al.
Publicado: (2015)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

Promising Role of Circulating Tumor Cells in the Management of SCLC
por: De Luca, Antonella, et al.
Publicado: (2021)

Correction to: Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Organoids as a Systems Platform for SCLC Brain Metastasis
por: Quaranta, Vito, et al.
Publicado: (2022)

Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC
por: Tapan, Umit, et al.
Publicado: (2020)

Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review
por: Chen, Shen, et al.
Publicado: (2019)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
por: Zhang, Chenxing, et al.
Publicado: (2020)

Baseline Ang-2 Serum Levels as a Predictive Factor for Survival in NSCLC and SCLC
por: Nikolakopoulou, Asimina, et al.
Publicado: (2022)

Surgery as a Potential Treatment Option for Patients With Stage III Small-Cell Lung Cancer: A Propensity Score Matching Analysis
por: Zhang, Chenyue, et al.
Publicado: (2019)

Low radiotherapy dose is suitable for brain metastases in SCLC compared with high dose
por: Xu, Liming, et al.
Publicado: (2023)

SCLC extensive disease – treatment guidance by extent or/and biology of response?
por: Eckert, Franziska, et al.
Publicado: (2008)

Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis
por: Wen, Pushuai, et al.
Publicado: (2018)

Killing SCLC: insights into how to target a shapeshifting tumor
por: Sutherland, Kate D., et al.
Publicado: (2022)

Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment
por: Lo, Ying-Chun, et al.
Publicado: (2023)

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
por: Li, Huihui, et al.
Publicado: (2023)

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy
por: Bütof, Rebecca, et al.
Publicado: (2017)

Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection
por: Guo, Yiying, et al.
Publicado: (2020)

Intratumor heterogeneity is associated with less CD8(+) T cell infiltration and worse survival in patients with small cell lung cancer
por: Zhang, Chenyue, et al.
Publicado: (2022)

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
por: Smith, Jarrod T., et al.
Publicado: (2020)

Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8(+) T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma
por: Zhang, Chenyue, et al.
Publicado: (2022)

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
por: Men, Yu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qque151mf8o2ed3gngglhomam8